ArticleExperimental and therapeutic medicine2016
Anti-inflammatory effects of oroxylin A on RAW 264.7 mouse macrophages induced with polyinosinic-polycytidylic acid.
Article in Experimental and therapeutic medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 37 citations in OpenAlex.
- A Comparative Study of TwoPlants (Basel, Switzerland) · 2024Article
- SIRT3 Activation a Promise in Drug Development? New Insights into SIRT3 Biology and Its Implications on the Drug Discovery Process.Journal of medicinal chemistry · 2024Review
- Anticancer potential of oroxylin A: from mechanistic insight to synergistic perspectives.Naunyn-Schmiedeberg's archives of pharmacology · 2023Review
- Flavonoids as Potential Anti-Inflammatory Molecules: A Review.Molecules (Basel, Switzerland) · 2022Review
- Evaluation of Urea-Based Inhibitors of the Dopamine Transporter Using the Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis.ACS chemical neuroscience · 2022Article
- Computer-aided drug design combined network pharmacology to explore anti-SARS-CoV-2 or anti-inflammatory targets and mechanisms of Qingfei Paidu Decoction for COVID-19.Frontiers in immunology · 2022Article
- Research Progress in Chinese Herbal Medicines for Treatment of Sepsis: Pharmacological Action, Phytochemistry, and Pharmacokinetics.International journal of molecular sciences · 2021Review
- Protective Effects of Oroxylin A on Retinal Ganglion Cells in Experimental Model of Anterior Ischemic Optic Neuropathy.Antioxidants (Basel, Switzerland) · 2021Article
- Berberine modulates hyper-inflammation in mouse macrophages stimulated with polyinosinic-polycytidylic acid via calcium-CHOP/STAT pathway.Scientific reports · 2021Article
- Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1α mediated XPC transcription.Oncogene · 2020Article
- Intracellular ROS Scavenging and Anti-Inflammatory Activities ofEvidence-based complementary and alternative medicine : eCAM · 2020Article
- B procyanidins of Annona crassiflora fruit peel inhibited glycation, lipid peroxidation and protein-bound carbonyls, with protective effects on glycated catalase.Scientific reports · 2019Article
- Anti-Inflammatory Effects ofNutrients · 2018Article
- Anti-Inflammatory Effect of Baicalein on Polyinosinic⁻Polycytidylic Acid-Induced RAW 264.7 Mouse Macrophages.Viruses · 2018Article
- The Role of Flavonoids in Inhibiting Th17 Responses in Inflammatory Arthritis.Journal of immunology research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oroxylin A (5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one; Baicalein 6-methyl ether) is an active flavonoid compound originally isolated from Scutellaria radix, which has been used to treat pulmonary infection in Korea, China, and Japan. Oroxylin A is known to possess dopamine reuptake inhibitor activity. However, the effects of oroxylin A on virus-induced macrophages has not been fully elucidated. In the present study, the anti-inflammatory effects of oroxylin A on double-stranded RNA-induced macrophages were examined. Production of nitric oxide (NO), various cytokines, as well as calcium release and the mRNA expression of signal transducer and activator of transcription 1 (STAT1) in dsRNA polyinosinic-polycytidylic acid (PIC)-induced RAW 264.7 mouse macrophages were evaluated. Oroxylin A restored the cell viability in PIC-induced RAW 264.7 mouse macrophages at concentrations of up to 50 µM. Additionally, oroxylin A significantly inhibited the production of nitric oxide (NO), interleukin (IL)-1α, IL-1β, IL-6, IL-10, interferon gamma-induced protein 10, granulocyte-colony stimulating factor (CSF), granulocyte macrophage-CSF, leukemia inhibitory factor (IL-6 class cytokine), lipopolysaccharide-induced CXC chemokine (LIX), monocyte chemoattractant protein 1, macrophage inflammatory protein (MIP)-1α, MIP-1β, MIP-2, Regulated on Activation, Normal T Expressed and Secreted, tumor necrosis factor-α, and vascular endothelial growth factor as well as calcium release and the mRNA expression of STAT1 in PIC-induced RAW 264.7 cells (P<0.05). Thus, the present results suggest that oroxylin A has anti-inflammatory properties, associated with its inhibition of NO, cytokines, chemokines and growth factors in PIC-induced macrophages via the calcium-STAT pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.